Overview
- 8 FDA inspections are on record.
- 2 inspections produced a Form 483.
- The most recent recorded inspection date is 2025-08-11.
At a glance
Inspections
8
Form 483s
2
EIRs
0
Last outcome
Form 483
Inspection history
FDA inspections on record, most recent first.
| Inspection | Category | Outcome | Form 483 |
|---|---|---|---|
| 4 Aug 2025 – 11 Aug 2025 | Human Drugs | 483 | View 483 → |
| 29 Jan 2025 – 4 Feb 2025 | Foods & Cosmetics | Clean | |
| 17 May 2022 – 19 May 2022 | Foods & Cosmetics | Clean | |
| 9 Sep 2019 – 13 Sep 2019 | Human Drugs | 483 | View 483 → |
| 29 Aug 2017 – 30 Aug 2017 | Foods & Cosmetics | Clean | |
| 27 Feb 2015 – 4 Mar 2015 | Human Drugs | Clean | |
| 29 Nov 2011 | Not recorded | Clean | |
| 21 Jul 2009 | Not recorded | Clean |
Observations on record
Form 483 observations cited at this site, most recent first.
11 Aug 2025
21 CFR 211.110(a)
Control procedures to monitor and validate performance
Cited by Inga M Warr, Tomika L Crafter, Nelson N Ayangho
11 Aug 2025
21 CFR 211.110(a)
Written in-process control procedures
Cited by Inga M Warr, Tomika L Crafter, Nelson N Ayangho
11 Aug 2025
21 CFR 211.166(c)(1)
Homeopathic drugs, assessment of stability
Cited by Inga M Warr, Tomika L Crafter, Nelson N Ayangho
11 Aug 2025
21 CFR 211.180(e)(2)
Review of problem drugs
Cited by Inga M Warr, Tomika L Crafter, Nelson N Ayangho
11 Aug 2025
21 CFR 211.22(d)
Procedures not in writing, fully followed
Cited by Inga M Warr, Tomika L Crafter, Nelson N Ayangho
Investigators
FDA investigators tied to this site in the record.
Inga M Warr1 insp.
Tomika L Crafter1 insp.
Nelson N Ayangho1 insp.
Kerry-Ann P Latham1 insp.
Marissa R Stough1 insp.
Shalonda L Gatewood1 insp.
Stephen G Mclane1 insp.
Shondra N Gipson1 insp.
Susan O Oladeji1 insp.
Markeesa M Scales1 insp.
Laura L Staples1 insp.
Mary A Millner1 insp.
Kimberly Dutzek1 insp.
Kip J Hanks1 insp.
Recurring citations
CFR citation patterns observed across this site's inspections.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.110(a) | Cited across public-safe Form 483 observations | 3x |
| 21 CFR 211.180(e)(2) | Cited across public-safe Form 483 observations | 2x |
| 21 CFR 211.160(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.165(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.166(c)(1) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.198(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.22(d) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.63 | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.67(b) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.68(a) | Cited across public-safe Form 483 observations | 1x |
Full site report
Get the verbatim findings behind Dee Cee Laboratories, Inc's 2 Form 483s
Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.
- The site's full inspection history, with every Form 483 and its outcome
- Warning letters and recalls tied to the company behind it
- Whether recurring CFR citations get closed out or repeat